Cyclosporin A

規格

59865-13-3CAS番号

611-907-1EC番号

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17IUPAC名

C62H111N11O12化学式

1202.6 g/mol分子量

cyclosporin A; Ciclosporin; cyclosporine; 59865-13-3; Sandimmune; Neoral; Sandimmun; Cyclosporine A; Ciclosporine; Neoplanta; Equoral; Gengraf; Ciclosporina; Ciclosporinum; Sang-35; Ciclosporin A; Sandimmun Neoral; Zinograf ME; Consupren; Mitogard; Optimmune; Atopica; SangCyA; NeuroSTAT; Restasis; S-Neoral; Cipol N; DTXSID0020365; VEVYE; Sang 35; Ikervis; ANTIBIOTIC S-7481F1; Cyclosporine microemulsion; Antibiotic S 7481F1; 83HN0GTJ6D; SDZ-OXL-400; CEQUA; VERKAZIA; CHEBI:4031; OL 27-400; OL-27-400; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; NSC-290193; S 7481F1; DTXCID00365; (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl); CsANeoral; NSC290193; CsA Neoral; CyA NOF; CyA-NOF; Cyclavance; Capimune; Capsorin; Deximune; Sporimune; Vanquoral; Atopica for Cats; Modulis for Cats; Modulis for Dogs; 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide deriv.; Restasis MultiDose; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((E,1R,2R)-1-hydroxy-2-methylhex-4-enyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; Optimmune Ophthalmic; Cyclosporine Modified; OL 27400; CycloSPORINE, Modfied; OL 27 400; RefChem:919442; Cyclosporine/Chondroitin PF; cyclosporine ophthalmic solution; L04AD01; S01XA18; Cyclosporine/Chondroitin Sulfate PF; 30-ethyl-33-(1-hydroxy-2-methylhex-4-enyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 611-907-1; cyclo(-((2S,3R,4R,6E)-3-Hydroxy-4-methyl-2-methylaminooct-6-enoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-); 30-ethyl-33-((E)-1-hydroxy-2-methylhex-4-enyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclosporin; Ramihyphin A; MFCD00274558; CSA; Ciclosporin [INN]; MLS001333756; Sigmasporin Microoral; Papilock Mini; SDZ-OXL 400; Abrammune; Imusporin; Seciera; Vekacia; Arpimune ME; Sandimmune Neoral; Ciclosporina Germed; Cyclosporine;Ciclosporin; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; CYA; SMR000058578; Cicloral (antibiotic); Cyclosporine [USAN]; Debio088; Cyclosporine [USAN:USP]; UNII-83HN0GTJ6D; Ciclosporine [INN-French]; Ciclosporinum [INN-Latin]; Ciclosporina [INN-Spanish]; Sigmasporin; Cyclokat; Papilock; Pulminiq; Zyclorin; CicloMulsion; Cyclosporine;; Ciclosporin;; CCRIS 1590; Sandimmun;; Ciclosporin DT; Cyclorin;; Ciclosporin CRS; Consupren S; Modusik-A; Neoral;; HSDB 6881; Ramihyphin A;; 1cyn; 2wfj; 4jjm; Cipol-N; ,32-undecaone; NCGC00016890-01; DRG-0275; Prestwick_731; CAS-59865-13-3; NSC 290193; CsA & IFN.alpha.; Cyclosporine/Ciclosporin; 1c5f; 2z6w; Cyclosporine manufacturer; Prestwick2_000435; Prestwick3_000435; CICLOSPORIN [JAN]; Cyclosporin A (Standard); CHEMBL160; Epitope ID:451241; Sang-2000; CYCLOSPORINE [HSDB]; CYCLOSPORINE [IARC]; CYCLOSPORIN A [MI]; SCHEMBL4442; CICLOSPORIN [MART.]; CYCLOSPORINE [VANDF]; Nova-22007; BSPBio_000450; CICLOSPORIN [WHO-DD]; CICLOSPORIN [WHO-IP]; Cyclosporin A & IFN.alpha.; MLS000028376; MLS002153454; MLS002207033; CYCLOSPORINE [USP-RS]; BPBio1_000496; GTPL1024; orb1310145; orb3141206; CHEBI:92233; HY-B0579R; ATH-002; CYCLOSPORINE [GREEN BOOK]; OLO-400; CB-01-09 MMX; CICLOSPORIN [EP MONOGRAPH]; CYCLOSPORINE [ORANGE BOOK]; GLXC-04692; GLXC-06801; HMS1569G12; HMS2089A09; HMS2096G12; HMS2230M14; HMS3713G12; Cyclosporin A - Bio-X trade mark; CYCLOSPORINE [USP IMPURITY]; 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); EX-A4110; HY-B0579; MSK10250; CYCLOSPORINE [USP MONOGRAPH]; Cyclosporine A; Ciclosporin A; CsA; Tox21_110667; Tox21_301849; BDBM50022815; CICLOSPORINUM [WHO-IP LATIN]; DE-076; EBC-27538; ST-603; Cyclosporin A, >=98.5% (TLC); AKOS015969287; AKOS015994720; Tox21_110667_1; CCG-208184; DB00091; FC20749; KS-1257; SDCCGSBI-0050230.P004; NCGC00093704-12; NCGC00164258-01; NCGC00164258-02; NCGC00164258-03; NCGC00255232-01; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; BC164336; BP-28432; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); OL-27400; SY012000; SBI-0050230.P003; C2408; C9611; M01532; Cyclosporin A, VETRANAL(TM), analytical standard; Q367700; SR-01000780563; SR-01000780563-3; BRD-K03222093-001-01-8; BRD-K13533483-001-03-0; Ciclosporin, European Pharmacopoeia (EP) Reference Standard; -undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29; Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid; Cyclosporine, United States Pharmacopeia (USP) Reference Standard; Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%; Cyclosporine, Pharmaceutical Secondary Standard; Certified Reference Material; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2; (R-(R*,R*-(E)))-CYCLIC(L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL-3-HYDROXY-N,4-DIMETHYL-L-2-AMINO-6-OCTENOYL-L-.ALPHA.-AMINOBUTYRYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL); 104250-72-8; 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone別名